--- title: "Oncology Institute (NASDAQ:TOI) Major Shareholder Jorey Chernett Purchases 30,000 Shares" type: "News" locale: "en" url: "https://longbridge.com/en/news/287214162.md" description: "Jorey Chernett, a major shareholder of The Oncology Institute (NASDAQ:TOI), purchased 30,000 shares at $4.09 each, totaling $122,700. This acquisition increased his ownership to 10,529,358 shares, valued at over $43 million. Chernett has made several recent purchases, including 20,000 shares at $3.10 and 125,000 shares at $3.11. Analysts have mixed ratings on TOI, with a consensus price target of $7.00." datetime: "2026-05-21T11:51:11.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287214162.md) - [en](https://longbridge.com/en/news/287214162.md) - [zh-HK](https://longbridge.com/zh-HK/news/287214162.md) --- # Oncology Institute (NASDAQ:TOI) Major Shareholder Jorey Chernett Purchases 30,000 Shares -logo-1200x675.png/query-dj0yMDIyMDMwMzA4MDkzNw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)The Oncology Institute, Inc. (NASDAQ:TOI - Get Free Report) major shareholder Jorey Chernett purchased 30,000 shares of Oncology Institute stock in a transaction that occurred on Tuesday, May 19th. The stock was acquired at an average price of $4.09 per share, for a total transaction of $122,700.00. Following the transaction, the insider directly owned 10,529,358 shares of the company's stock, valued at $43,065,074.22. The trade was a 0.29% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC. Jorey Chernett also recently made the following trade(s): - On Thursday, April 9th, Jorey Chernett purchased 20,000 shares of Oncology Institute stock. The stock was bought at an average price of $3.10 per share, with a total value of $62,000.00. - On Tuesday, March 24th, Jorey Chernett purchased 125,000 shares of Oncology Institute stock. The stock was bought at an average price of $3.11 per share, with a total value of $388,750.00. - On Friday, March 20th, Jorey Chernett purchased 25,000 shares of Oncology Institute stock. The stock was bought at an average price of $3.35 per share, with a total value of $83,750.00. - On Tuesday, March 17th, Jorey Chernett purchased 75,000 shares of Oncology Institute stock. The stock was bought at an average price of $3.42 per share, with a total value of $256,500.00. - On Monday, March 16th, Jorey Chernett purchased 60,985 shares of Oncology Institute stock. The stock was bought at an average price of $3.29 per share, with a total value of $200,640.65. - On Friday, March 13th, Jorey Chernett purchased 263,000 shares of Oncology Institute stock. The stock was bought at an average price of $2.92 per share, with a total value of $767,960.00. ## Oncology Institute Trading Up 2.4% * * * * * * TOI opened at $4.20 on Thursday. The firm has a market cap of $415.13 million, a P/E ratio of -11.35 and a beta of 0.33. The stock has a 50-day moving average of $3.43 and a 200 day moving average of $3.32. The Oncology Institute, Inc. has a 12 month low of $2.02 and a 12 month high of $4.88. Oncology Institute (NASDAQ:TOI - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.05. The company had revenue of $147.44 million during the quarter, compared to the consensus estimate of $142.10 million. On average, research analysts forecast that The Oncology Institute, Inc. will post -0.2 earnings per share for the current fiscal year. ## Wall Street Analysts Forecast Growth A number of analysts recently issued reports on TOI shares. B. Riley Financial raised their price target on Oncology Institute from $6.00 to $8.00 and gave the stock a "buy" rating in a research report on Friday, March 13th. Needham & Company LLC reissued a "buy" rating and issued a $5.00 price objective on shares of Oncology Institute in a research report on Monday, March 9th. BTIG Research reissued a "buy" rating and issued a $7.00 price objective on shares of Oncology Institute in a research report on Monday, March 9th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Oncology Institute in a research report on Monday, April 20th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $7.00. **View Our Latest Analysis on Oncology Institute** ## Institutional Investors Weigh In On Oncology Institute Several large investors have recently added to or reduced their stakes in TOI. Kestra Advisory Services LLC purchased a new stake in Oncology Institute in the 4th quarter valued at about $31,000. Pekin Hardy Strauss Inc. bought a new stake in Oncology Institute during the 4th quarter valued at $36,000. Cetera Investment Advisers raised its position in Oncology Institute by 35.0% during the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company's stock valued at $36,000 after purchasing an additional 4,545 shares in the last quarter. State of Wyoming bought a new stake in Oncology Institute during the 2nd quarter valued at $37,000. Finally, R Squared Ltd bought a new stake in Oncology Institute during the 4th quarter valued at $41,000. 36.86% of the stock is owned by hedge funds and other institutional investors. ## About Oncology Institute (Get Free Report) The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. ## Further Reading - Five stocks we like better than Oncology Institute - The Palantir Paradox—Record Numbers and a Stock That Won't Cooperate - TJX Companies Fires on All Cylinders With 9% Revenue Growth - From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook - AI Consolidation Begins: Blackstone & Google Forge an AI Empire _This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to \[email protected\]._ Insider Buying or Selling at Oncology Institute? Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Oncology Institute and related companies. From Our Partners SpaceX eyes a 1.75 trillion valuation - here's what to know Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a... Brownstone Research Iran's New Leader Just Said Something That Should Terrify Every American Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ... American Alternative $30 stock to buy before Starlink goes public (WATCH NOW!) In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno... Paradigm Press Trump's gold order: the announcement they won't put on the front page On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb... Reagan Gold Group My feud with Zohran Mamdani Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac... Stansberry Research Iran War Shock: What I Was Told In That Private Meeting You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th... Banyan Hill Publishing Why this tiny stock may move before the SpaceX IPO drops The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio... Behind the Markets Your book attached Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug... Profits Run ### Related Stocks - [TOI.US](https://longbridge.com/en/quote/TOI.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [XHS.US](https://longbridge.com/en/quote/XHS.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [IHF.US](https://longbridge.com/en/quote/IHF.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [RILY.US](https://longbridge.com/en/quote/RILY.US.md) - [RILYL.US](https://longbridge.com/en/quote/RILYL.US.md) - [RILYN.US](https://longbridge.com/en/quote/RILYN.US.md) - [TOIIW.US](https://longbridge.com/en/quote/TOIIW.US.md) - [RILYG.US](https://longbridge.com/en/quote/RILYG.US.md) - [RILYK.US](https://longbridge.com/en/quote/RILYK.US.md) - [RILYP.US](https://longbridge.com/en/quote/RILYP.US.md) - [RILYZ.US](https://longbridge.com/en/quote/RILYZ.US.md) - [RILYT.US](https://longbridge.com/en/quote/RILYT.US.md) ## Related News & Research - [Insider Buying: Oncology Institute (NASDAQ:TOI) Major Shareholder Buys 30,000 Shares of Stock](https://longbridge.com/en/news/287100653.md) - [Oncology Institute (NASDAQ:TOI) Major Shareholder Buys $83,750.00 in Stock](https://longbridge.com/en/news/280181601.md) - [GatePass Capital LLC Invests $1.28 Million in The Oncology Institute, Inc. $TOI](https://longbridge.com/en/news/287617920.md) - [Is UHS Rebalancing Its Healthcare Portfolio or Drifting Strategically After Recent Leadership and GW Moves?](https://longbridge.com/en/news/288014713.md) - [Hinge Health Inc. (NYSE:HNGE) Given Consensus Recommendation of "Moderate Buy" by Analysts](https://longbridge.com/en/news/288239675.md)